Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Maraviroc in Rheumatoid Arthritis

ClinicalTrials.gov ID: NCT00427934

Public ClinicalTrials.gov record NCT00427934. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 10:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of Maraviroc in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate

Study identification

NCT ID
NCT00427934
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Pfizer
Industry
Enrollment
128 participants

Conditions and interventions

Interventions

  • Maraviroc Drug
  • Maraviroc Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2007
Primary completion
Sep 30, 2008
Completion
Sep 30, 2008
Last update posted
Nov 4, 2014

2007 – 2008

United States locations

U.S. sites
21
U.S. states
13
U.S. cities
17
Facility City State ZIP Site status
Pfizer Investigational Site Huntington Beach California 92646
Pfizer Investigational Site San Francisco California 94115
Pfizer Investigational Site Hamden Connecticut 06518
Pfizer Investigational Site Meriden Connecticut 06450
Pfizer Investigational Site New Haven Connecticut 06510-2716
Pfizer Investigational Site New Haven Connecticut 06511-5473
Pfizer Investigational Site Daytona Beach Florida 32114
Pfizer Investigational Site Port Orange Florida 32127
Pfizer Investigational Site Savannah Georgia 31405
Pfizer Investigational Site Savannah Georgia 31406
Pfizer Investigational Site Moline Illinois 61265
Pfizer Investigational Site Madisonville Kentucky 42431
Pfizer Investigational Site Kalamazoo Michigan 49007
Pfizer Investigational Site Kalamazoo Michigan 49048
Pfizer Investigational Site Omaha Nebraska 68154
Pfizer Investigational Site Las Vegas Nevada 89128
Pfizer Investigational Site Syracuse New York 13210
Pfizer Investigational Site Hickory North Carolina 28601
Pfizer Investigational Site Hickory North Carolina 28602
Pfizer Investigational Site Minot North Dakota 58701
Pfizer Investigational Site Duncansville Pennsylvania 16635

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 23 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00427934, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 4, 2014 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00427934 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →